Favipiravir CAS 259793-96-9 T-705 Purity ≥99.0% (HPLC) COVID-19 API Factory High Quality

Short Description:

Chemical Name: Favipiravir; T-705

CAS: 259793-96-9

Appearance: White to Off-White Powder

Purity: ≥99.0% (HPLC)

In the treatment of Influenza Virus Infections and COVID-19

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer with High Purity and Stable Quality
Commercial Supply Favipiravir and Related Intermediates:
Favipiravir CAS 259793-96-9
2-Aminopropanediamide CAS 62009-47-6
Diethyl Aminomalonate Hydrochloride CAS 13433-00-6
3,6-Dichloropyrazine-2-Carbonitrile CAS 356783-16-9
3,6-Difluoropyrazine-2-Carbonitrile CAS 356783-28-3
6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile CAS 356783-31-8
6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS 259793-88-9
3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8

Chemical Properties:

Chemical Name	Favipiravir
Synonyms	T-705; 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide
CAS Number	259793-96-9
CAT Number	RF-API18
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C5H4FN3O2
Molecular Weight	157.1
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Powder
Identification 1H-NMR	Consistent with proposed structure
Identification HPLC	Retention time of main peak in sample preparation should be correspond with the retention time of main peak in reference standard preparation
Identification Mass	Mass Spectrum is consistent with proposed structure
Melting Point	188.0℃-193.0℃
Related Substances (Area Normalization)	Any Single Impurity: ≤0.10% (HPLC)
Related Substances (Area Normalization)	Total Impurities: ≤1.0% (HPLC)
Purity / Analysis Method	≥99.0% (HPLC)
Moisture (K.F)	≤0.50%
Residue on Ignition	≤0.10%
Heavy Metals	≤20ppm
Residue Solvents
Methanol	≤3000ppm
Isopropanol	≤5000ppm
n-Heptane	≤5000ppm
Ethanol	≤5000ppm
Test Standard	Enterprise Standard
Usage	Active Pharmaceutical Ingredient (API); Treatment of COVID-19

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Cardboard drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Favipiravir (T-705) (CAS 259793-96-9) is one of the 5 compounds recommended by WHO for the investigation of treatment of COVID-19. Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.